Literature DB >> 28413134

The in vitro MIMIC® platform reflects age-associated changes in immunological responses after influenza vaccination.

Allison Dauner1, Pankaj Agrawal2, Jose Salvatico3, Tenekua Tapia4, Vipra Dhir5, S Farzana Shaik6, Donald R Drake7, Anthony M Byers8.   

Abstract

Increasing research and development costs coupled with growing concerns over healthcare expenditures necessitate the generation of pre-clinical testing models better able to predict the efficacy of vaccines, drugs and biologics. An ideal system for evaluating vaccine immunogenicity will not only be reliable but also physiologically relevant, able to be influenced by immunomodulatory characteristics such as age or previous exposure to pathogens. We have previously described a fully autologous human cell-based MIMIC® (Modular IMmune In vitro Construct) platform which enables the evaluation of innate and adaptive immunity in vitro, including naïve and recall responses. Here, we establish the ability of this module to display reduced antibody production and T cell activation upon in vitro influenza vaccination of cells from elderly adults. In the MIMIC® system, we observe a 2.7-4.2-fold reduction in strain-specific IgG production to seasonal trivalent influenza vaccine (TIV) in the elderly when compared to adults, as well as an age-dependent decline in the generation of functional antibodies. A parallel decline in IgG production with increasing age was detected via short-term ex vivo stimulation of B cells after in vivo TIV vaccination in the same cohort. Using MIMIC®, we also detect a reduction in the number but not proportion of TIV-specific multifunctional CD154+IFNγ+IL-2+TNFα+ CD4+ T cells in elderly adults. Inefficient induction of multifunctional helper T cells with TIV stimulation in MIMIC® despite a normalized number of initial CD4+ T cells suggests a possible mechanism for an impaired anti-TIV IgG response in elderly adults. The ability of the MIMIC® system to recapitulate differential age-associated responses in vitro provides a dynamic platform for the testing of vaccine candidates and vaccine enhancement strategies in a fully human model including the ability to interrogate specific populations, such as elderly adults.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Elderly; Human; Immunosenescence; In vitro; Influenza; MIMIC®

Mesh:

Substances:

Year:  2017        PMID: 28413134     DOI: 10.1016/j.vaccine.2017.03.099

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

Review 1.  Engineering in vitro immune-competent tissue models for testing and evaluation of therapeutics.

Authors:  Jennifer H Hammel; Jonathan M Zatorski; Sophie R Cook; Rebecca R Pompano; Jennifer M Munson
Journal:  Adv Drug Deliv Rev       Date:  2022-01-11       Impact factor: 15.470

2.  Immunogenicity and protective efficacy of RSV G central conserved domain vaccine with a prefusion nanoparticle.

Authors:  Jennifer N Rainho-Tomko; Vincent Pavot; Michael Kishko; Kurt Swanson; Darin Edwards; Heesik Yoon; Lilibeth Lanza; Judith Alamares-Sapuay; Robert Osei-Bonsu; Sophia T Mundle; Dave A Murison; Scott Gallichan; Simon Delagrave; Chih-Jen Wei; Linong Zhang; Gary J Nabel
Journal:  NPJ Vaccines       Date:  2022-06-30       Impact factor: 9.399

Review 3.  Cell and tissue engineering in lymph nodes for cancer immunotherapy.

Authors:  Alexander J Najibi; David J Mooney
Journal:  Adv Drug Deliv Rev       Date:  2020-08-01       Impact factor: 15.470

Review 4.  Advanced model systems and tools for basic and translational human immunology.

Authors:  Lisa E Wagar; Robert M DiFazio; Mark M Davis
Journal:  Genome Med       Date:  2018-09-28       Impact factor: 11.117

5.  Introduction.

Authors:  Stephen J Streatfield; Jerzy Karczewski; Vidadi Yusibov
Journal:  Vaccine       Date:  2017-08-18       Impact factor: 3.641

Review 6.  A roadmap for translational cancer glycoimmunology at single cell resolution.

Authors:  Andreia Peixoto; Andreia Miranda; Lúcio Lara Santos; José Alexandre Ferreira
Journal:  J Exp Clin Cancer Res       Date:  2022-04-15

7.  T-Cell Dependent Immunogenicity of Protein Therapeutics Pre-clinical Assessment and Mitigation-Updated Consensus and Review 2020.

Authors:  Vibha Jawa; Frances Terry; Jochem Gokemeijer; Shibani Mitra-Kaushik; Brian J Roberts; Sophie Tourdot; Anne S De Groot
Journal:  Front Immunol       Date:  2020-06-30       Impact factor: 7.561

8.  Meeting report: Global vaccine and immunization research forum, 2018.

Authors:  Peter Dull; Martin Friede; Angela Hwang; B Fenton Hall
Journal:  Vaccine       Date:  2019-10-14       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.